BMS Trumpets Breakthrough For Phase III-Bound IPF Drug
Strong Showing For LPA1 Antagonist
Executive Summary
Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.
You may also be interested in...
Bristol Myers Squibb Gets A Second Hit In Pulmonary Fibrosis
Phase III trials of BMS-986278 are already being prepped.
Asthma And RSV Will Be Hot Topics At ERS 2023
Elsewhere at the European Respiratory Society meeting, Bristol Myers Squibb will hope that its LPA1 antagonist can add a hit in progressive pulmonary fibrosis to the success it has already posted in the idiopathic form of the disease.
Another IPF Drug Failure As Galecto Therapy Suffers Mid-Stage Flop
Galecto’s decision to discontinue its idiopathic pulmonary fibrosis candidate after disappointing Phase IIb results represents the latest in a number of mid/late-stage failures to treat the disease.